Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Neurostimulation of the Vagus Nerve for the Relief of Acute Bronchoconstriction Due to Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Is between the ages of 18 and 70 years.~2. Has been admitted to an emergency care facility with a working diagnosis of bronchoconstriction due to asthma.~3. Has an FEV1\<60% predicted.~4. Is available and willing to return for an office visit at 7 days and participate in a 30-day telephone call from time of discharge from the ED.~5. Is able to give written Informed Consent, or his/her legally authorized representative is available to give written Informed Consent.~Exclusion Criteria:~1. Has a history of lung cancer, chronic obstructive pulmonary disease (COPD), or other co-morbidity due to irreversible narrowing of the airways.~2. Is at risk of imminent respiratory collapse:~   * Lung Function: FEV1 \< 25% predicted~  * Signs and symptoms of extreme respiratory distress at rest, such as accessory muscle use, chest retraction~  * Consciousness State: Drowsy, confused~  * Rapid deterioration in respiratory status (sudden change in respiratory rate, decrease in oxygen saturation, change in consciousness, etc).~3. Has an abscess or other infection or lesion (including lymphadenopathy) at the therapy head placement site.~4. Has known or suspected atherosclerotic cardiovascular disease, carotid artery disease (e.g. bruits or history of TIA or CVA) or congestive heart failure (CHF).~5. Has suspected or confirmed sepsis.~6. Has a clinically significant irregular heart rate or rhythm.~7. Clinically significant changes in blood pressure or is receiving pressors to maintain blood pressure.~8. Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.~9. Has a history of carotid endarterectomy or vascular neck surgery on the right side.~10. Has been implanted with metal cervical spine hardware.~11. Has a condition that would interfere with VAS Dyspnea self-assessment.~12. Is pregnant.~13. Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.~14. Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- AlphaCore System (Type: EXPERIMENTAL): non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System

Based on this trial design, predict the completion outcome and termination type (if applicable).